Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23822912 | 0.86 | TNK2 (0.35) | CTSLCTSBCTSKBACE1BACE2 | |
| SCHEMBL12295037 | 0.86 | TNK2 (0.35) | CTSLCTSBCTSKBACE1BACE2 | |
| SCHEMBL18666852 | 0.86 | TNK2 (0.35) | CTSLCTSBCTSKBACE1BACE2 | |
| SCHEMBL18667233 | 0.83 | TNK2 (0.35) | LMNATNK2TAAR1HRH4HRH3 | |
| SCHEMBL14052168 | 0.83 | TNK2 (0.35) | BACE1LMNATNK2TAAR1HRH4 | |
| SCHEMBL12294892 | 0.83 | TNK2 (0.35) | LMNATNK2TAAR1HRH4HRH3 | |
| SCHEMBL18666910 | 0.83 | TNK2 (0.35) | LMNATNK2TAAR1HRH4HRH3 | |
| SCHEMBL18666854 | 0.83 | TNK2 (0.35) | BACE1LMNATNK2TAAR1HRH4 | |
| SCHEMBL23822848 | 0.82 | TNK2 (0.33) | LMNATNK2TAAR1HRH4HRH3 | |
| SCHEMBL14052073 | 0.79 | POLRMT (0.38) | LMNATNK2TAAR1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |